The writer argues patents pushed rivals to build better GLP-1s, noting monthly prices falling from over $1,000 to as little as $149, and generics expected in the early 2030s.
Recap by typeshit. Full story at Fortune.
Costco is adding Novo Nordisk's semaglutide shots to what it offers. Details are thin here, so tap through for how pricing and access will work.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
A Facebook post says rapid weight loss on these drugs can raise gallstone risk, and lists warning signs like severe upper belly pain, fever and yellow eyes.
TheStreet looks at what that means for patients paying up to $1,500 a month for peptide therapy and how the ruling could affect what they pay.
Loading…